{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RNS60", "query": { "intervention": "RNS60" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 9, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T00:28:01.697Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04693715", "title": "Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stroke, Ischemic" ], "interventions": [ { "name": "RNS60", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revalesio Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2021-07-07", "completion_date": "2023-11-08", "has_results": true, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-09-04T00:28:01.697Z", "location_count": 7, "location_summary": "Chicago, Illinois • Portland, Oregon • Philadelphia, Pennsylvania + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04693715" }, { "nct_id": "NCT01057498", "title": "Safety Study of Nebulized RNS60 to Treat Asthma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "RNS60", "type": "DRUG" }, { "name": "RNS60 - single dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revalesio Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2010-05", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2012-01-12", "last_synced_at": "2026-09-04T00:28:01.697Z", "location_count": 2, "location_summary": "Cypress, California • Stanford, California", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01057498" }, { "nct_id": "NCT01511302", "title": "Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "RNS60", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" }, { "name": "Budesonide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revalesio Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 65, "start_date": "2012-06", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2014-07-28", "last_synced_at": "2026-09-04T00:28:01.697Z", "location_count": 4, "location_summary": "Costa Mesa, California • Los Angeles, California • Riverside, California", "locations": [ { "city": "Costa Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01511302" }, { "nct_id": "NCT02525471", "title": "A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALS" ], "interventions": [ { "name": "RNS60", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sabrina Paganoni, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 24, "start_date": "2015-10", "completion_date": "2017-10-18", "has_results": true, "last_update_posted_date": "2021-05-28", "last_synced_at": "2026-09-04T00:28:01.697Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02525471" }, { "nct_id": "NCT01714089", "title": "Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsing Remitting Multiple Sclerosis" ], "interventions": [ { "name": "RNS60 125 ml", "type": "DRUG" }, { "name": "RNS60 250 ml", "type": "DRUG" }, { "name": "Interferon beta 1a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revalesio Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2016-04-06", "last_synced_at": "2026-09-04T00:28:01.697Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01714089" }, { "nct_id": "NCT02005523", "title": "Study of RNS60 on Pain and Function After Hip Labral Repair", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hip Labral Tear" ], "interventions": [ { "name": "RNS60", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revalesio Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": null, "summary": "Not listed" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2015-02-06", "last_synced_at": "2026-09-04T00:28:01.697Z", "location_count": 1, "location_summary": "Tacoma, Washington", "locations": [ { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02005523" }, { "nct_id": "NCT02497222", "title": "Pilot Study of RNS60 in Allergen-induced Bronchoconstriction", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "RNS60", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revalesio Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-09-04T00:28:01.697Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02497222" }, { "nct_id": "NCT03456882", "title": "The Effect of RNS60 on ALS Biomarkers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "RNS60", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mario Negri Institute for Pharmacological Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 147, "start_date": "2017-05-30", "completion_date": "2021-05-30", "has_results": true, "last_update_posted_date": "2023-04-21", "last_synced_at": "2026-09-04T00:28:01.697Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03456882" }, { "nct_id": "NCT01264783", "title": "Safety and Tolerability of RNS60 Given by IV to Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myocardial Infarct" ], "interventions": [ { "name": "RNS60", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revalesio Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 12, "start_date": "2011-07", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2011-10-04", "last_synced_at": "2026-09-04T00:28:01.697Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01264783" } ] }